Herpes Simplex Virus Type I Stromal Keratitis
Conditions
Keywords
Herpes Simplex Virus Type I, Stromal Keratitis
Brief summary
This study aims to compare the clinical efficacy and safety of BD111 injection in combination with standard therapy vs. standard therapy in herpes simplex virus type I stromal keratitis (HSK), providing preliminary confirmation of the clinical effectiveness of BD111 in combination with standard therapy.
Detailed description
This is a phase Ⅱa, single-blind, single-dose, randomized, positively controlled clinical trial of BD111 in patients with herpes simplex virus type I stromal keratitis (HSK) aged 18 to 70 years. Forty eligible participants will be recruited in the trial. BD111 is investigational new biologics (Injection)--a type of lentiviral-like particle that can simultaneously deliver SpCas9 and gRNA targeting the HSV-1 virus gene, also known as HSV-1-erasing lentiviral particles (HELP). The total follow-up duration was 12 months, the safe endpoints and efficacy endpoints will be used to assess the efficacy, safety and tolerability profiles in patients with HSK.
Interventions
GENETICBD111 Injection (investigational new drug)
BD111: intrastromally injection, single-dosing 10E6 TU/eye, specified injection volume is 0.15mL.
COMBINATION_PRODUCTTriple-drugs therapy of HSV-1 stromal keratitis
Triple-drugs therapy: Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops for 3 weeks.
Sponsors
Shanghai BDgene Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Participants must meet all of the following inclusion criteria to be enrolled in this study. 1. Aged 18 to 70 years old; 2. Clinically diagnosed with herpes simplex virus stromal keratitis; 3. Tear swab HSV-1 nucleic acid test (qPCR method) positive; 4. No use of systemic antiviral drugs or corticosteroids within 48 hours before enrollment; 5. No systemic immune eye diseases; 6. Good eyelid structure and blinking function; 7. Eye structure and function assessment showing potential for visual recovery; 8. No retinal detachment, with generally normal visual function; 9. No history of corneal trauma; 10. Visual acuity in the fellow eye is better than 20/200; 11. Fertile males or females must use highly effective contraceptive methods (such as oral contraceptives, intrauterine devices, abstinence, or barrier contraception combined with spermicides) during the trial and continue contraception for 12 months after administration; 12. Participants voluntarily join the study, sign an informed consent form, have good compliance, and cooperate with follow-up visits.
Exclusion criteria
Patients with any of the following conditions cannot be enrolled in this study 1. Active ocular infection caused by other pathogens in the target eye or the fellow eye within 30 days before enrollment, including but not limited to blepharitis, infectious conjunctivitis, keratitis, scleritis, and endophthalmitis; 2. Patients with bilateral viral keratitis 3. Previous corneal transplant surgery in the study eye; 4. A history of adverse reactions or allergies to corticosteroids and sodium fluorescein, allergies to therapeutic or diagnostic protein products, allergies to ≥ two drugs or non-drug factors, or having an ongoing allergic disease; 5. Absence of tear film and blinking function; 6. Severe dry eye disease; 7. Malignant ocular surface tumor; 8. Glaucoma; 9. Patients with systemic autoimmune diseases; 10. Signs of systemic infection before enrollment, including fever and receiving antibiotic treatment (abnormal elevating values in white blood cells, lymphocytes, and neutrophils in routine blood tests); 11. Abnormal major organ function or other uncontrolled clinical problems, mainly including but not limited to the following: * Severe kidney disease history, serum creatinine ≥ 133μmol/L; * Liver dysfunction, transaminase level ≥ 80 IU/L; * Uncontrolled hypertension, systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg; * Uncontrolled diabetes, fasting blood glucose greater than or equal to 8.0 μmol/L; * Cardiovascular disease history, with arrhythmia, myocardial ischemia, and myocardial infarction (diagnosed by electrocardiogram examination); * Platelet level ≤ 100×10\^9/μL or ≥ 450×10\^9/μL due to any cause, hemoglobin level lower than 10.0g/dL (male) or 9.0g/dL (female). 12. HIV infection; 13. Pregnant and lactating women (pregnancy in this trial is defined as a positive urine pregnancy test); 14. Participation in other drug or medical device clinical trials; 15. Alcohol or drug abuse; 16. Lack of compliance with the trial or the ability to sign an informed consent form; 17. Other situations deemed unsuitable for participation in the trial by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical cure rate of HSK at Day 70 and Day112 post-administration | 12 months | Definition of HSK clinical cure: disappearance of the subject's clinical symptoms, disappearance of active inflammatory lesions on ophthalmologic examinations, and successful clearance of the HSV-1 viral genome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The percentage of participants with failed clearance of HSV-1 viral genome in tears at Day 14, Day 28, Day 70, Day 112, Day 180, and Day 365 post-administration | 12 months | The failure of HSV-1 viral genome clearance is determinated by HSV-1 positive results of qPCR test. HSV-1 positive definition of qPCR test: qPCR Ct value ≤ 36, or qPCR Ct value is 36 \< Ct value \< 40 and the Ct value of repetitive qPCR test is ≤ 36, or results of both qPCR tests are 36 \< Ct value \< 40. |
| The percentage of participants with HSK recurrence at Day 180, and Day 365 post-administration | 12 months | Definition of HSK recurrence: HSV-1 nucleic acid qPCR test is positive, and clinical symptoms presents again, and ophthalmic examinations find active inflammatory lesions on interventional eye. |
| Score change of corneal inflammation scale post-administration | 12 months | From baseline to Day 70, Day 112, Day 180, and Day 365 post-administration. |
| The improvement in best corrected visual acuity (BCVA) | 12 months | From baseline to Day 70, Day 112, Day 180, and Day 365 post-administration. |
| The improvement in corrected distance visual acuity (CDVA) post-administration | 12 months | From baseline to Day 70, D11ay 2, Day 180, and Day 365 post-administration. |
| Anti-p24 antibody in blood | 12 months | At Day 14, Day 28, Day 112, Day 180, and Day 365 post-administration. |
| The percentage of participants with successful clearance of HSV-1 viral genome in tears at Day 14, Day 28, Day 70, Day 112, Day 180, and Day 365 post-administration | 12 months | The definition of successful HSV-1 clearance: negative results in tear swab HSV-1 nucleic acid tests on two consecutive samplings (interval ≥14 days). The definition of a negative result in tear swab HSV-1 nucleic acid test: single qPCR Ct value = 40 or undetected, or Ct value of the first qPCR test 36 \< Ct value \< 40, and the Ct value of repetitive qPCR test is 40 or undetected. |
| Anti-BD111 antibody in blood | 12 months | At Day 14, Day 28, Day 112, Day 180, and Day 365 post-administration. |
| Vector RNA copy number in tear fluid | 12 months | Vector persistence times: Tear fluid vector RNA copy number at Day 112, Day 180, and Day 365 post-administration. |
| Circular DNA copy number in blood | 12 months | Vector persistence times: circular DNA copy number in blood at Day 112, Day 180, and Day 365 post-administration. |
| Off-target Detection | 6 months | BD111 off-target detection (DNA deep sequencing) in eye swabs at Day 14 and Day 180 post-administration |
| The characteristics of adverse events (AEs) and serious adverse events (SAEs) | 12 months | AEs and SAEs are recorded and evaluated (type, incidance, severity etc.), including ocular and systemic AEs/SAEs post-administration. |
| Anti-Cas9 antibody in blood | 12 months | At Day 14, Day 28, Day 112, Day 180, and Day 365 post-administration. |
Countries
China
Contacts
Primary ContactChen Wei, M.D.
Backup ContactMa Huixiang, M.D.
Outcome results
None listed